TrialJournal of Alzheimer's disease : JAD2017

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.

Mercè Boada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.